FDA
-
-
-
-
-
-
-
Nabriva (NBRV) Announces September 16 as Date of 1:25 Reverse Stock Split
-
-
-
-
-
-
-
Nabriva Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
-
-
-
-
-
-
-
Nabriva Therapeutics Provides Business Update and Announces Preliminary Financial Results for the Fourth Quarter of 2021
-
-
-
-
-
-
-
Acurx Pharmaceuticals Joins the Antimicrobials Working Group
-
-
-
-
-
-
-
Nabriva Commences Exclusive Distribution of SIVEXTRO® (tedizolid phosphate) in the U.S.
-
-
-
-
-
-
-
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
-
-
-
-
-
-
-
Nabriva (NBRV) and Sinovant Sciences Restructure License Agreement for XENLETA for Community-Acquired Bacterial Pneumonia in China
-
312,667 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

